Northwest Biotherapeutics (STU:NBYB) Tariff Resilience Score: 6/10 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NBYB Northwest Biotherapeutics Inc STU:NBYB
17 GF Score
Price €0.15
GF Value €0.24
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Northwest Biotherapeutics Tariff Resilience Score?

Northwest Biotherapeutics STU:NBYB +3.45% 17 Tariff Resilience Score is 6 as of Jul. 21, 2026. GuruFocus rates STU:NBYB with a GF Score™ of 17/100 and a GF Value™ of €0.24 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,370 Biotechnology companies, Northwest Biotherapeutics ranks better than 75.99% on this metric.

Northwest Biotherapeutics has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Northwest Biotherapeutics has Northwest Biotherapeutics faces moderate tariff exposure due to its reliance on international clinical trials and manufacturing. However, its focus on innovative cancer therapies, often exempt from tariffs, and strategic partnerships help mitigate some risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Northwest Biotherapeutics might have Average Resilient.

Northwest Biotherapeutics  (STU:NBYB) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Northwest Biotherapeutics Tariff Resilience Score Related Terms

STU:NBYB vs LCTX, VRXA, ABEO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Northwest Biotherapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Northwest Biotherapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Tariff Resilience Score falls into.


STU:NBYB
17GF Score
Northwest Biotherapeutics Inc STU:NBYB
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Northwest Biotherapeutics (STU:NBYB) has a Tariff Resilience Score of 6 as of Jul. 21, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Northwest Biotherapeutics ranks #329 out of 1370 companies in the Biotechnology industry, placing it in the top 24%.
Is Northwest Biotherapeutics' Tariff Resilience Score too high?
Northwest Biotherapeutics' current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Northwest Biotherapeutics' value of 6 is 50% above this industry median. Based on the distribution chart, Northwest Biotherapeutics ranks #329 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Northwest Biotherapeutics has a GF Score™ of 17/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Northwest Biotherapeutics' Tariff Resilience Score compare to LCTX and VRXA?
According to the Biotechnology industry distribution chart, Northwest Biotherapeutics ranks #329 out of 1370 companies for Tariff Resilience Score. This places Northwest Biotherapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Northwest Biotherapeutics' value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Northwest Biotherapeutics's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Northwest Biotherapeutics's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Northwest Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Northwest Biotherapeutics (STU:NBYB) is currently considered Possible Value Trap. The stock's GF Value™ is €0.24, compared to a current price of €0.15 — trading 37.5% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Northwest Biotherapeutics' overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Northwest Biotherapeutics (STU:NBYB), the current Tariff Resilience Score is 6 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Northwest Biotherapeutics (STU:NBYB) Overvalued in 2026?

Based on GuruFocus' analysis, Northwest Biotherapeutics stock appears to be undervalued. The current stock price of €0.15 is trading 37.5% below its estimated GF Value™ of €0.24. GuruFocus considers Northwest Biotherapeutics to be Possible Value Trap.

Key valuation signals for STU:NBYB:

  • Tariff Resilience Score: 6
  • GF Value™: €0.24 vs. price of €0.15 (37.5% below fair value)
  • GF Score™: 17/100 with 5 warning signs
  • Industry Position: 50% above the Biotechnology median (#329 of 1370)

No single metric tells the full story. See the STU:NBYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Northwest Biotherapeutics Business Description

Other Exchanges NWBO:USA
Address 4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc a biotechnology company focused on developing personalized immune therapies for cancer. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S Food and Drug Administration.
17GF Score

Get the complete analysis for STU:NBYB

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.24
GF Value